ArticleClinical endocrinology2026
Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing.
Article in Clinical endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Guiding Management of Bethesda V Thyroid Nodules: The Role of Molecular Testing.Clinical endocrinology · 2026Article
- Inside the Matrix: Integrated Cytology and Molecular Testing of Thyroid FNAC Samples Using a Commercial Synthetic 3D Scaffold.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe 2023 Bethesda System update introduced molecular testing as a management option for Bethesda V cytology nodules, aiming to guide surgical decision-making. This study investigates the correlation between molecular profiling and malignancy aggressiveness.
designWe conducted a retrospective multicenter study involving patients with Bethesda V cytology and confirmed malignant pathology who underwent molecular profiling between 2018 and 2021. PATIENTS: A total of 156 patients with Bethesda V cytology and final malignant histology were included. MEASUREMENTS: Malignancy aggressiveness was assessed based on histopathological features following 2015 ATA guidelines. Demographic data, pathology results, and genetic variants were analyzed. Molecular profiling results were stratified according to variant risk levels.
resultsWe identified 161 Bethesda V nodules, of which 153 (95.0%) were malignant on final pathology. Genetic stratification revealed no detected mutations in 39.7% (n = 56), low-risk (n = 49, 31.4%), and intermediate-risk variants (n = 45, 28.8%). Only one patient had a high-risk variant. Patients with intermediate-risk variants had a sixfold risk of aggressive disease compared to those with low-risk variants (49% vs. 8.2%, p < 0.001). RAS mutations were the most common among the low-risk group (68.8%) and BRAF V600E predominated in the intermediate-risk group (93.3%).
conclusionsOur findings suggest that molecular profiling offers insights into risk stratification for Bethesda V thyroid lesions, demonstrating a very low incidence of aggressive pathology in the low-risk molecular group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.